Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Calciferol

(Ergocalciferol)

ApprovedSmall molecule

Jazz Pharmaceuticals

Ergocalciferol is a form of vitamin D used to treat or prevent vitamin D deficiency, which can cause weak bones and muscles. It helps your body absorb calcium and maintain healthy bones.[2] Calciferol is currently approved and in use across 78 indications[4].[1]

Calciferol is one of 1303 small molecule programs targeting Liver Disease. It is currently in Approved.

78

Indications

28

Total Trials

2

Active Trials

1,302

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Liver DiseaseApproved

Malignant Colon NeoplasmActive, not recruiting

HypoparathyroidismActive, not recruiting

COVID-19Active, not recruiting

HyperparathyroidismActive, not recruiting

Cardiovascular DiseaseActive, not recruiting

InfertilityActive, not recruiting

Prediabetes SyndromeActive, not recruiting

Muscle SpasmActive, not recruiting

Thyroid NeoplasmActive, not recruiting

Liver DiseaseApproved

Approved

Malignant Colon NeoplasmPreclinical

Active, not recruiting

HypoparathyroidismApproved

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

HyperparathyroidismPreclinical

Active, not recruiting

Cardiovascular DiseasePreclinical

Active, not recruiting

InfertilityPreclinical

Active, not recruiting

Prediabetes SyndromePreclinical

Active, not recruiting

Muscle SpasmPreclinical

Active, not recruiting

Thyroid NeoplasmPreclinical

Active, not recruiting

Showing 10 of 78 indications

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Calciferol

Jazz Pharmaceuticals

Adenocard

Voltaren

Zolymbus

MS Contin

HHikma Pharmaceuticals LLC

Duragesic-100

Sporanox

SSebela Pharmaceuticals Development LLC

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Recombinant Human Endostatin

PPeking University Third Hospital

Tianeptine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

ApprovedRecruiting

Sarcoidosis

NCT03621553

Q1 2030

Phase 2Recruiting

Neuropathy

NCT05259527

Clinical

Trials by Indication[1]

Chronic Kidney Disease5 trials

hCAP18 Levels and Vitamin D Deficiency in Chronic Kidney Disease

Withdrawn·MMassachusetts General Hospital·N/A·NCT01026363

Vitamin D Supplement Study for Stage Three and Four Chronic Kidney Disease (CKD) Patients

Terminated·TThe Cleveland Clinic·Phase 3·NCT01173848·19 enrolled

Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D

Terminated·—·Phase 4·NCT01312441·20 enrolled

Show 2 more trials

Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients

Completed·SSalem Veterans Affairs Medical Center·Phase 4·NCT00958451·80 enrolled

Vitamin D, Chronic Kidney Disease (CKD) and the Microcirculation

Completed·BBarts & The London NHS Trust·Phase 4·NCT00882401·64 enrolled

Vitamin D Deficiency4 trials

Is Treatment of Vitamin D Deficiency Associated With Resolution of Statin-Induced Muscular Symptoms

Completed·—·Phase 4·NCT01568255·11 enrolled

hCAP18 Levels and Vitamin D Deficiency in Healthy Subjects

Completed·MMassachusetts General Hospital·N/A·NCT00742235·99 enrolled

Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity

Completed·WWeill Medical College of Cornell University·Phase 4·NCT00288873·60 enrolled

Show 1 more trial

Vitamin D Deficiency in Adults Following a Major Burn Injury

Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT05084248·48 enrolled

Vitamin D4 trials

DIVINE: Dialysis Infection and Vitamin D In New England

Completed·MMassachusetts General Hospital·N/A·NCT00892099·105 enrolled

Effect of Vitamin D Oral Supplements on 25 OH Vitamin D Levels

Completed·KKing Faisal Specialist Hospital & Research Center·N/A·NCT01170494·279 enrolled

The Effects of Vitamin D and Calcium Supplementation to Parathyroid Hormone in CHB Patients Treated With TDF

Completed·MMahidol University·Phase 4·NCT05313477·64 enrolled

Show 1 more trial

Effects of Vitamin D Supplementation on Antimycobacterial Immunity

Completed·BBarts & The London NHS Trust·N/A·NCT00157066·230 enrolled

Rheumatoid Arthritis2 trials

Treatment of Vitamin D Deficiency in Patients With Rheumatoid Arthritis

Completed·JJohns Hopkins University·N/A·NCT01426347·139 enrolled

Vitamin D Effect in Rheumatoid Arthritis.

Completed·TTanta University·Phase 4·NCT04472481·20 enrolled

Dialysis Patients2 trials

Vitamin D 2 to Dialysis Patients

Terminated·—··NCT00535158·18 enrolled

Ergocalciferol Therapy in Calcidiol Deficient, Hemodialysis Patients on Therapeutic Doses of Paricalcitol

Completed·UUniversity of Utah·Phase 1·NCT02011828·58 enrolled

11 more indications

Coronary Artery Disease1 trial

Vitamin D Repletion in Coronary Artery Disease

Completed·—·N/A·NCT01570309·96 enrolled

Type 1 Diabetes1 trial

Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes

Completed·—·Phase 2/3·NCT03046927·48 enrolled

Cardiovascular Disease1 trial

Vitamin D and Inflammatory Markers of Cardiovascular Disease in African Americans With Type 2 Diabetes

Unknown status·CCook County Health·Phase 4·NCT01153243·117 enrolled

Chronic pain1 trial

Immune Mechanisms of Vitamin D to Reduce Chronic Pain After Burn

Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT05619289·40 enrolled

Pilot Study1 trial

Pilot Study: The Effect of Ergocalciferol on Plasma Mucin-1 Levels

Completed·WWake Forest University Health Sciences·Phase 1·NCT03747523·44 enrolled

Dysmenorrhea1 trial

The Role of Vitamin D Supplementation on Pain in Women With Primary Dysmenorrhea and Hypovitaminosis D

Unknown status·MMahidol University·N/A·NCT04829487·36 enrolled

Neuropathy1 trial

Vitamin D Supplementation on Reported Rates of Taxane-Induced Neuropathy

Recruiting·VVirginia Commonwealth University·Phase 2·NCT05259527·120 enrolled

Cystic Fibrosis1 trial

Improving Vitamin D Status In Cystic Fibrosis

Completed·—·N/A·NCT00450073·30 enrolled

Hypovitaminosis D1 trial

Optimal Doses of Ergocalciferol Supplementation for Treatment of Hypovitaminosis D in Adults

Unknown status·—·Phase 4·NCT03228862·360 enrolled

Hypercalciuria1 trial

Vitamin D Repletion in Stone Formers With Hypercalciuria

Completed·NNew York Presbyterian Hospital·Phase 4·NCT01295879·30 enrolled

Sarcoidosis1 trial

Vitamin D Homeostasis in Sarcoidosis

Recruiting·UUniversity of Texas Southwestern Medical Center·Approved·NCT03621553·90 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

DRISDOL

NDA NDA003444

Sources

References

[1]
ClinicalTrials.gov — 28 trial records for Ergocalciferol. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Calciferol drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Ergocalciferol compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Ergocalciferol. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA003444). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Jazz Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Vitamin D Receptor Agonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Jazz Pharmaceuticals

Related News